Monomorphic Post-Transplant Lymphoproliferative Disorder in Pediatric
Solid Organ Transplant Recipients: Treatment Approach Across Canada
Abstract
There are no standardized pediatric treatment protocols for monomorphic
post-transplant lymphoproliferative disorder (PTLD). We reviewed data
from Canadian pediatric centers to determine patient characteristics,
treatment approaches and outcomes. There were 55 eligible children
diagnosed with monomorphic PTLD between January 2001-December 2021.
Forty-nine (89%) underwent reduction of immunosuppression. The
majority, 44 (80%), received rituximab, 40/44 (91%) with concurrent
chemotherapy. A total of 46 (84%) children received chemotherapy:
LMB-96 (48%) and low-dose cyclophosphamide with prednisone (30%) being
the favored regimens. Projected 3-year event-free survival and overall
survival was 62% and 77%, respectively. Approach to monomorphic PTLD
treatment was relatively consistent across Canada.